Bupivacaine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: The Bupivacaine Shortage in 2026

Bupivacaine Hydrochloride Injection has been on the FDA and ASHP drug shortage lists since June 2023. Nearly three years later, supply remains inconsistent across multiple formulations and concentrations. For anesthesiologists, surgeons, pain management specialists, and other proceduralists, the shortage has forced ongoing adaptations in clinical practice, procurement, and patient communication.

This briefing covers the current state of the shortage, clinical implications, alternative protocols, and tools to help your patients maintain access.

Shortage Timeline

Understanding the trajectory of this shortage provides context for current supply conditions:

• Early 2023: Baxter discontinues 0.75% Bupivacaine in 8.25% dextrose 2 mL ampules, removing a key spinal anesthesia formulation from the U.S. market.
• June 2023: Bupivacaine Hydrochloride Injection is formally listed on the FDA drug shortage database. ASHP confirms multiple concentrations affected.
• Late 2023: FDA authorizes temporary importation of Bupivacaine Hydrochloride Injection ampules from foreign manufacturers to help bridge the gap.
• 2024: Pfizer reports back orders on Marcaine 0.75% 10 mL preservative-free vials with estimated resupply dates that are repeatedly pushed back. Other manufacturers (Hospira, Fresenius Kabi, Auromedics) experience intermittent production challenges.
• 2025: Sporadic improvement in some concentrations (particularly 0.25% and 0.5% with preservative), but preservative-free and spinal formulations remain severely constrained.
• Early 2026: The shortage persists. ASHP continues to list Bupivacaine as actively in shortage with no confirmed resolution date.

Prescribing and Clinical Implications

The prolonged shortage has several practical consequences for providers:

Formulary Constraints

Many hospitals and surgical centers have implemented Bupivacaine conservation protocols, including:

• Restricting use of specific concentrations to high-priority procedures
• Mandating substitution with Ropivacaine for peripheral nerve blocks and epidurals
• Reserving preservative-free formulations for neuraxial (spinal/epidural) use only
• Utilizing Lidocaine for shorter procedures where Bupivacaine's long duration isn't essential

Alternative Agent Selection

The clinical alternatives for providers include:

• Ropivacaine (Naropin): The primary substitute. Similar onset and duration to Bupivacaine with a more favorable cardiac safety profile. Slightly less potent at equivalent concentrations. FDA-approved for epidural, nerve block, and local infiltration. Note: Ropivacaine supply has also experienced intermittent pressure due to substitution demand.
• Lidocaine: Widely available, faster onset, shorter duration (1–2 hours). Suitable for shorter procedures. May require continuous infusion for extended coverage.
• Mepivacaine (Carbocaine): Intermediate duration (2–3 hours). Useful for dental and shorter peripheral nerve blocks.
• Chloroprocaine: Ultra-short acting ester-type local anesthetic. May be appropriate for very short spinal anesthetics or when amide agents are contraindicated.
• Exparel (Liposomal Bupivacaine): Provides up to 72 hours of analgesia via surgical site infiltration or nerve block. Different indication profile — not for epidural or intrathecal use. Cost is significantly higher ($285–$365/vial).

For a patient-facing resource you can share, see: Alternatives to Bupivacaine.

Current Availability Picture

As of early 2026, availability varies significantly by manufacturer, concentration, and whether the formulation is preservative-free:

• Most constrained: 0.75% preservative-free (critical for spinal anesthesia); Marcaine Spinal
• Intermittently available: 0.5% and 0.25% with preservative; Bupivacaine with epinephrine
• Relatively more available: 0.25% preservative-free in some regions; lower-volume formulations from secondary manufacturers

FDA-authorized imported Bupivacaine (typically in ampule form rather than vials) may be available through major distributors. Providers should verify that imported products are on the FDA's temporary importation authorization list.

Cost and Access Considerations

Bupivacaine is a relatively inexpensive generic — a 50 mL vial of 0.5% generic Bupivacaine typically costs $9 to $40. However, shortage conditions have introduced pricing variability:

• Facilities may see higher acquisition costs from secondary or specialty distributors
• Imported formulations may carry different pricing structures
• The shift to Ropivacaine can increase per-procedure anesthetic costs depending on institutional contracts
• Exparel substitution substantially increases cost ($285–$365 per vial)

For patients concerned about costs, you can direct them to: How to Save Money on Bupivacaine.

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers helps you direct patients to pharmacies and facilities that have Bupivacaine in stock. During shortage conditions, this can reduce canceled procedures and patient frustration.

ASHP Drug Shortage Database

The ASHP maintains detailed shortage entries for Bupivacaine with manufacturer-specific notes, estimated resupply dates, and therapeutic alternatives. This should be part of your regular shortage monitoring workflow.

FDA Drug Shortage Database

The FDA's database includes information on temporary importation authorizations, which is critical for procurement teams evaluating imported supply.

Institutional Strategies

• Establish a Bupivacaine conservation protocol with your pharmacy and therapeutics committee
• Cross-train clinical staff on Ropivacaine dosing equivalencies and technique adjustments
• Set up automated alerts through your GPO or distributor for restocked formulations
• Maintain a formulary substitution algorithm that accounts for procedure type and patient factors

Looking Ahead

The sterile injectable drug shortage crisis extends beyond Bupivacaine — it's a systemic issue affecting dozens of critical medications. Industry groups, the FDA, and Congress have taken steps to address root causes (manufacturing quality incentives, supply chain transparency requirements), but meaningful resolution will take years.

In the meantime, providers who stay informed, maintain flexible protocols, and leverage tools like Medfinder will be best positioned to maintain patient care continuity.

Final Thoughts

The Bupivacaine shortage is a stress test for anesthesia and surgical practice. While alternatives exist and imported supply helps bridge gaps, the situation requires ongoing vigilance. Keep your teams informed, your protocols updated, and your patients supported with clear communication about what the shortage means for their care.

Related resources:

• How to Help Your Patients Find Bupivacaine in Stock
• Bupivacaine Shortage Update for Patients (2026)
• How to Help Patients Save Money on Bupivacaine